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(HCV) infection and cirrhosis have a higher risk for liver-related ache (18%). Only one patient (1.7%) experienced a serious adverse
complications and have historically been more difficult to cure
than patients without cirrhosis. We evaluated the safety and effi-
cacy of ombitasvir/paritaprevir/ritonavir and dasabuvir, without
ribavirin, for 12 weeks in patients with HCV genotype 1b infec-
tion and compensated cirrhosis.
Methods: Treatment-naïve and peginterferon/ribavirin
treatment-experienced patients received 12 weeks of
ombitasvir/paritaprevir/ritonavir (25/150/100 mg once daily)
and dasabuvir (250 mg twice daily). Key inclusion criteria were
hemoglobin P10 g/dl, albumin P2.8 g/dl, platelet count
P25  109/L, creatinine clearance P30 ml/min, and Child-Pugh
score 66. Efficacy was assessed by the percentage of patients
achieving SVR (HCV RNA <25 IU/ml) 12 weeks post-treatment
(SVR12). Efficacy and safety were assessed in all patients receiv-
ing study drug.
Results: Sixty patients with HCV genotype 1b infection and cir-
rhosis received treatment. The study population comprised 62%
male, 55% treatment-experienced, 83% with IL28B non-CC geno-
type, 22% with platelet count <90  109/L, and 17% with albumin
<3.5 g/dl. All 60 patients completed treatment, and SVR12 was
achieved in 100% (95% CI, 94.0–100%) of patients. The most com-Journal of Hepatology 20
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adverse events.event. Laboratory abnormalities were infrequently observed and
not clinically significant.
Conclusions: TheHCVregimenof ombitasvir/paritaprevir/ritonavir
and dasabuvir without ribavirin for 12 weeks achieved 100% SVR12
and was well tolerated in HCV genotype 1b-infected patients with
cirrhosis, suggesting that this 12-week ribavirin-free regimen is suf-
ficient in this population.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Among seven recognized genotypes (GTs) of hepatitis C virus
(HCV), GT1 is the most common HCV infection, accounting for
46–60% of cases worldwide [1,2]. Subgenotype 1b encompasses
approximately 68% of all GT1 infections and is the most prevalent
subgenotype in Europe, Central America, Middle East, and Asia.
Patients with chronic HCV infection and cirrhosis are at greatest
risk for progression to decompensation, end-stage liver disease
and disease-related death, hepatocellular carcinoma, and liver
transplantation [3]. As a result, the recommendations from the
American Association for the Study of Liver Diseases (AASLD),
Infectious Disease Society of America (IDSA), and the European
Association for the Study of the Liver (EASL) prioritize these
patients for treatment [4,5]; however, achieving a sustained viro-
logic response (SVR) has been more challenging in patients with
cirrhosis. First-generation protease inhibitors in combination
with pegylated interferon (PegIFN) and ribavirin (RBV) achieved
low rates of response in these patients (33–77%), in part due to
significant toxicities leading to drug discontinuation [6–8]. New
IFN-free direct-acting antiviral (DAA) therapies have greatly
improved SVR rates in patients with cirrhosis, nonetheless, rates
are still lower than in patients without cirrhosis [9–13].16 vol. 64 j 301–307
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Furthermore, longer treatment and/or the addition of RBV has
been required with most regimens to maximize SVR rates in
patients with cirrhosis [9,11,12,14,15]. As the prevalence and
burden of HCV cirrhosis is projected to increase significantly in
the coming years [16,17], treatments that optimize SVR in
patients with cirrhosis are greatly needed.
Ombitasvir (OBV) is an NS5A inhibitor co-formulated with the
NS3/4A protease inhibitor paritaprevir (PTV) and the pharma-
cokinetic enhancer ritonavir (r), which increases peak and trough
drug exposures allowing for once daily PTV dosing [18].
Administered with the non-nucleoside NS5B polymerase inhibi-
tor dasabuvir (DSV), this multi-targeted 3-DAA regimen with or
without RBV is approved in many countries to treat HCV GT1
infection. Approval for the treatment of HCV GT1 patients with
compensated cirrhosis was based on the evidence of a phase III
trial of 380 patients with compensated cirrhosis in which OBV/
PTV/r and DSV plus RBV achieved SVR rates at post-treatment
week 12 (SVR12) of 91.8% and 95.9% after 12 or 24 weeks of ther-
apy, respectively [9]. SVR12 rates were 98.5% (67/68) in those
infected with GT1b receiving 12 weeks of treatment, and 100%
(51/51) following 24 weeks of treatment. In that study, all
patients received RBV, leading to the treatment recommendation
of OBV/PTV/r and DSV plus RBV for 12 weeks in patients with
GT1b infection and cirrhosis [4,5,19]. However, RBV is not
required in GT1b-infected patients without cirrhosis in whom
100% SVR12 was achieved in 301 patients who received
OBV/PTV/r and DSV without RBV for 12 weeks [20–22] and the
high rates of SVR achieved in those with compensated cirrhosis
raises the question of whether RBV is necessary for GT1b-
infected patients with cirrhosis. Eliminating RBV in this popula-
tion with cirrhosis without sacrificing efficacy is expected to
improve the safety profile, particularly with respect to anemia
and hyperbilirubinemia.
We report the results of the TURQUOISE-III phase IIIb,
open-label study designed to assess the safety and efficacy of
OBV/PTV/r and DSV without RBV for 12 weeks in adults with
chronic HCV GT1b infection and compensated cirrhosis, both
with or without prior treatment experience with PegIFN/RBV.Patients and methods
Study patients
Patients 18 years or older were eligible for enrollment if they had HCV genotype
1b infection for at least 6 months prior to screening, or an HCV RNA of >1000 IU/
ml at the time of screening with a liver biopsy consistent with chronic HCV infec-
tion. Eligible patients had documented cirrhosis by means of liver biopsy (META-
VIR score >3 or Ishak score of >4) or transient elastography (FibroScan score
P12.5 kPa within 6 months of screening or during screening), and a Child-Pugh
score of 5 or 6 with no evidence of decompensation or hepatocellular carcinoma.
Those with a positive test result for hepatitis B or human immunodeficiency virus
were excluded. Laboratory eligibility criteria were a serum albumin P2.8 g/dl,
calculated creatinine clearanceP30 ml/min, hemoglobinP10 g/dl, platelet count
P25  109/L, total bilirubin 63.0 mg/dl, and an international normalized ratio
61.8. Treatment-experienced patients were allowed with documented treatment
failure with PegIFN/RBV at least 2 months prior to screening; prior treatment
experience with any DAA or investigational agent was not permitted. More
detailed eligibility criteria are provided in the Supplementary data.
Study design
All patients in this phase IIIb, open-label study were assigned to receive 12 weeks
of OBV/PTV/r and DSV without RBV. Co-formulated OBV/PTV/r was administered302 Journal of Hepatology 201once daily (25/150/100 mg) and DSV 250 mg twice daily. Patients were followed
up to 24 weeks post-treatment. Written informed consent was obtained from
each patient and the study protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori approval by the institutional
review board of each study site.
Efficacy, safety, and pharmacokinetic assessments
Plasma samples collected at screening and each study visit were processed by a
central laboratory for HCV RNA levels using the Roche TaqMan real-time reverse
transcriptase-PCR assay version 2.0. Efficacy was assessed by the percentage of
patients with SVR12, defined as a HCV RNA below the lower limit of quantifica-
tion (LLOQ = 25 IU/ml) 12 weeks after last dose of study drug. The first primary
endpoint was non-inferiority of the SVR12 rates achieved with OBV/PTV/r and
DSV for 12 weeks to the historical SVR12 rate achieved by sofosbuvir plus
PegIFN/RBV in HCV GT1b-infected patients with cirrhosis (73.2%, 95% confidence
interval [CI] 59.8–83.2%). Non-inferiority of the 3-DAA regimen could be claimed
if the SVR12 95% CI lower limit was greater than the upper limit of the CI for the
historical rate minus a 10.5% non-inferiority margin (72.7%). The second primary
endpoint was superiority of the 3-DAA SVR12 rate to the historical SVR12 rate for
sofosbuvir plus PegIFN/RBV in this patient population (83.2%). Secondary assess-
ments included the percentage of patients with on-treatment virologic failure,
and post-treatment relapse. Further details of historical non-inferiority calcula-
tions are provided in the Supplementary data.
Treatment-emergent adverse events (AEs) were collected from the start of
study drug administration until 30 days after the last dose and were assessed
by the investigators for relation to study drug and severity. Serious AEs were col-
lected from the time of signed consent until 30 days after last study drug dose.
Clinical laboratory chemistry and hematology tests were assessed throughout
the study.
Blood samples were collected at baseline for IL28B (IFNL4-rs12979860) geno-
typing [23]. Blood samples for the pharmacokinetic assessment of the study drugs
were collected at treatment weeks 2, 4, 8, and 12. Plasma concentrations of OBV,
PTV, r, DSV, and DSV M1 metabolite were determined using a validated liquid
chromatography method with tandem mass spectrometric detection with LLOQ
of 0.462, 0.601, 4.93, 4.58, and 4.77 ng/ml, respectively. Drug concentrations sum-
marized as trough levels (Ctrough) were binned based on sample collection time
within the 22–26 h or 10–14 h bins for once or twice daily drugs, respectively.
Statistical analyses
Efficacy and safety analyses were performed using all patients receiving at least
one dose of study drug. The 2-sided 95% CIs for binomial proportions were calcu-
lated using the Wilson score method. With a sample size of 60 patients, an
observed SVR12 rate of 90% (95% CI 79.9–95.3%) would provide >90% power to
demonstrate non-inferiority to the historical sofosbuvir plus PegIFN/RBV rate.
An interim analysis was planned after all patients reached post-treatment week
12 or prematurely discontinued the study. SAS (SAS Institute) for the UNIX oper-
ating system was used for all analyses.Results
Baseline patient demographics and characteristics
Screening of patients occurred from September 19, 2014 through
to November 28, 2014 at 19 sites in the United States, Canada,
and Belgium. Of 72 patients screened, 12 did not meet inclu-
sion/exclusion criteria; 60 were enrolled and received study drug.
Demographics and disease characteristics are presented in
Table 1. The majority of patients had prior treatment experience
with PegIFN/RBV, and had IL28B (IFNL4-rs12979860) [23] non-CC
genotype. At baseline, 19 (31.7%) patients had surrogate markers
for portal hypertension and/or hepatic synthetic dysfunction: 13
had baseline thrombocytopenia (platelet count <90  109/L), 10
had baseline hypoalbuminemia (serum albumin <3.5 g/dl), and
4 had both surrogate markers. Of 41 patients enrolled with a cir-
rhosis determination by FibroScan, 20 had baseline scores of
>20 kPa.6 vol. 64 j 301–307
Table 1. Baseline patient demographics and disease characteristics.
Characteristic OBV/PTV/r + DSV
N = 60
Male 37 (61.7)
White race 52 (86.7)
Hispanic/Latino ethnicity 3 (5.0)
Age, median years (range) 60.5 (26.0-78.0)
BMI, median kg/m2 (range) 27.0 (18.0-42.3)
IL28B non-CC genotype 50 (83.3)
PegIFN/RBV experienceda
Non-responderb
Relapser/breakthroughc
Otherd
33 (55.0)
18 (30.0)
5 (8.3)
10 (16.7)
HCV RNA, median log10 IU/ml (range) 6.8 (3.8-7.5)
Former injection drug use 20 (33.3)
Cirrhosis determination
Biopsy
FibroScan
19 (31.7)
41 (68.3)
FibroScan, kPa
Median (range)
>20 KPa
19.0 (12.5-67.8)
20 (48.8)e
FibroTest, median (range) 0.89 (0.27-0.99)
Albumin, g/dl
Median (range)
<3.5
4.0 (2.8-4.5)
10 (16.7)
Platelet count, 109/L
Median (range)
<90
132 (54-514)
13 (21.7)
Alpha fetoprotein, ng/ml
Median (range)
≥20
11.9 (2.7-247.0)
20 (33.3)
Total bilirubin, mg/dl
Median (range)
>1.5
0.8 (0.3-2.5)
9 (15.0)
INR, median (range) 1.1 (0.9-1.3)
Esophageal varices 7 (11.7)
Values are n (%) unless denoted otherwise.
aDefinitions for prior treatment experience are provided in Supplementary data.
bPatients with documented null or partial response to prior PegIFN/RBV treat-
ment, or non-responders with insufficient documentation of unquantifiable HCV
RNA to distinguish between partial and null response.
cPatients with documented relapse to prior PegIFN/RBV treatment, or less well-
characterized breakthrough/relapse.
dPatients with IFN-intolerance, or inadequate documentation of response to prior
PegIFN/RBV.
eN = 41.
OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; DSV, dasabuvir; SD, standard
deviation; BMI, body mass index; INR; international normalized ratio; IFN,
interferon; RBV, ribavirin.
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Fig. 1. Virologic response during and after treatment with OBV/PTV/r + DSV
for 12 weeks. The percentage of patients achieving HCV RNA <25 IU/ml response
at different time points is plotted with 95% CI using the Wilson score method. The
horizontal dashed line indicates the non-inferiority margin for the historical rate
achieved with sofosbuvir plus PegIFN/RBV (72.7%), and the horizontal solid line
indicates the superiority threshold (83.2%). RVR, rapid virologic response at
treatment week 4; EOTR, end of treatment response at week 12; SVR4, sustained
virologic response at post-treatment week 4; SVR12, sustained virologic response
at post-treatment week 12.
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All 60 patients completed 12 weeks of treatment with OBV/PTV/r
and DSV. Rapid serum HCV RNA decline was observed with 61.7%
of patients (37/60) below LLOQ at treatment week 2, and 100%
(60/60) below LLOQ by week 4 through to the end of treatment.
After 12 weeks of treatment, 100% (95% CI, 94.0–100%) of patients
achieved SVR12 (Fig. 1). Thus, the SVR12 rate of OBV/PTV/r and
DSV was both non-inferior and superior to the historical rate
achieved with sofosbuvir plus PegIFN/RBV in GT1b-infected
patients with cirrhosis.
All baseline patient characteristics that have historically been
predictive of poor response to treatment, including those identi-
fied in HCV GT1 patients with cirrhosis treated with OBV/PTV/rJournal of Hepatology 201and DSV plus RBV (prior null response to PegIFN/RBV and former
injection drug use [9]), had no impact on SVR12 rates. Similarly,
baseline laboratory abnormalities or measures of liver disease
severity associated with reduced SVR12 rates with IFN and/or
DAA-containing regimens, including serum albumin, platelet
count, alpha fetoprotein, interferon-c inducible protein 10, and
FibroScan score did not influence the 100% SVR12 rate achieved.
Improvement in laboratory assessments
Liver enzyme mean values rapidly declined by week 2 of treat-
ment. Aminotransferases were normalized at the end of treat-
ment in 45/53 (84.9%) patients with elevated baseline alanine
aminotransferase (ALT), and 41/55 (74.5%) patients with elevated
aspartate aminotransferase (AST). Mean improvements in labora-
tory values at post-treatment week 12 were also observed for
albumin (+0.31 g/dl), alpha fetoprotein (24.0 ng/ml), total
bilirubin (0.3 mg/dl), and FibroTest (0.16).
Safety outcomes
The majority of patients had AEs (76.7%; Table 2), though no
patient discontinued the study. The most common AEs were fati-
gue in 13 (21.7%) patients, diarrhea in 12 (20.0%) patients, and
headache in 11 (18.3%) patients. Of these patients, 8 with fatigue,
6 with diarrhea, and 6 with headache had events assessed as pos-
sibly related to study drug. Most AEs were mild or moderate, and
only one patient experienced a severe event (Table 2). This
patient experienced serious events of acute hypotension and syn-
cope secondary to hypotension requiring hospitalization on day
2. At study start, this patient was taking metoprolol, lisinopril,
and nisoldipine to treat hypertension. Due to CYP3A4 inhibition
by ritonavir possibly leading to increased nisoldipine exposures,
a 50% dosage adjustment to nisoldipine was recommended prior
to study start, but was not initiated. Following the serious events,
nisoldipine was discontinued with concurrent lisinopril dose
increase, which stabilized the patient’s blood pressure. Study
drug was interrupted from day 3 to 8, whereupon treatment
was re-initiated and this patient achieved SVR12.6 vol. 64 j 301–307 303
Table 2. Proportion of patients with treatment-emergent AEs and laboratory
abnormalities.
Event OBV/PTV/r + DSV
N = 60
Any AE 46 (76.7)
Severe AE 1 (1.7)
Serious AE 1 (1.7)
AE leading to study discontinuation 0
Common AEs (≥10% of patients)
Fatigue
Diarrhea
Headache
Arthralgia
Dizziness
Insomnia
Pruritus
13 (21.7)
12 (20.0)
11 (18.3)
6 (10.0)
6 (10.0)
6 (10.0)
6 (10.0)
Hemoglobin
Grade 2 (<10-8 g/dl)
Grade 3 (<8-6.5 g/dl)
1 (1.7)*
0
Total bilirubin
Grade 2 (>1.5-3 x ULN)
Grade 3 (>3-10 x ULN)
12 (20.0)
0
Alanine aminotransferase
Grade 3 (>5-20 x ULN) 1 (1.7)
Aspartate aminotransferase
Grade 3 (>5-20 x ULN) 0
Values are n (%).
⁄Grade 2 hemoglobin abnormality (9.9 g/dl) occurred at a single visit.
OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; DSV, dasabuvir; ULN, upper limit
of normal.
Table 3. Comparison of trough plasma concentrations from TURQUOISE-III
and TURQUOISE-II.
TURQUOISE-III TURQUOISE-II
Study drug N Geometric mean
(arithmetic 
mean, %CV)
N Geometric mean
(arithmetic
mean, %CV)
Ombitasvira 38 28.3
(32.2, 53)
242 24.5
(28.7, 68)
Paritaprevira 38 108
(382.4, 204)
242 66.9
(227, 257)
Ritonavira 38 67.6
(123.0, 146)
242 62.6
(132, 185)
Dasabuvirb 35 290
(391, 88)
231 250
(324, 96)
Dasabuvir M1b 35 82.0
(119, 111)
231 72.2
(93.9, 84)
The units for geometric and arithmetic means are ng/ml.
aBinned time interval of >22–26 h.
bBinned time interval of >10–14 h.
CV, coefficient of variation.
Research ArticlePost-baseline laboratory abnormalities were infrequent, not
clinically significant, and no grade 4 abnormalities were observed
(Table 2). Total bilirubin elevations were the most common lab-
oratory abnormalities observed occurring in 12 (20.0%) patients.
Hyperbilirubinemia was primarily attributed to increases in indi-
rect bilirubin, consistent with the inhibition of the organic anion-
transporting protein 1B1 and 1B3 by paritaprevir, and were not
accompanied by concurrent aminotransferase elevations. Seven
of the 12 patients experiencing post-baseline grade 2 elevations
in total bilirubin had abnormalities at baseline, including four
with grade 2 total bilirubin elevations. The highest total bilirubin
value observed during treatment in any patient was 3.0 mg/dl
(1.6 mg/dl indirect bilirubin). One patient experienced a grade 2
hemoglobin decline (9.9 g/dl) at week 12; this male patient had
a baseline hemoglobin level of 11.3 g/dl, below the lower limit
of normal. Aminotransferase elevations were observed in one
patient. This 77-year old woman had asymptomatic coincident
grade 3 ALT and grade 2 AST elevations at day 16 that decreased
at the next study visit and normalized during the post-treatment
period.
Pharmacokinetic results
Trough plasma concentrations of OBV, PTV, r, DSV, and DSV M1
metabolite were generally comparable to the Ctrough levels
observed in GT1-infected population receiving 12 or 24 weeks
of OBV/PTV/r and DSV plus RBV in the phase III TURQUOISE-II
trial (Table 3) [9]. Ctrough values of OBV, PTV, r, DSV, and DSV
M1 metabolite observed in TURQUOISE-III were 16%, 61%, 8%,
16%, and 14% higher, respectively, than those from TURQUOISE-II.304 Journal of Hepatology 201Discussion
Patients with HCV infection and cirrhosis are at the highest risk
for progression to hepatic decompensation, transplantation,
liver-related and all-cause mortality. Studies have shown that
HCV eradication in patients with cirrhosis can reduce the risk
of liver decompensation, hepatocellular carcinoma, morbidity,
and improve hepatic synthetic function [24–26]. In this study,
treatment with OBV/PTV/r and DSV without RBV resulted in a
SVR12 rate of 100% in HCV GT1b-infected patients with compen-
sated cirrhosis, meeting the primary endpoints of non-inferiority
and superiority to the SVR12 rate of sofosbuvir plus PegIFN/RBV.
These results are consistent with the SVR12 rates achieved in
patients from phase III trials including 68 patients with GT1b-
infection and cirrhosis who received OBV/PTV/r and DSV with
RBV for 12 weeks (98.5%) and 301 patients without cirrhosis
who received the 3-DAAs alone for 12 weeks (100%) [9,20–22].
These data suggest that RBV does not provide incremental effi-
cacy benefit in patients with cirrhosis with GT1b infection when
treated with OBV/PTV/r and DSV.
The results of this trial can be compared to data available for
other IFN-free DAA regimens either under investigation or
already approved. Although guidelines recommend 24 weeks of
ledipasvir/sofosbuvir alone or ledipasvir/sofosbuvir with RBV
for 12 weeks in patients with cirrhosis who have failed prior ther-
apy [5], the 12-week RBV-free combination of ledipasvir and
sofosbuvir led to SVR12 rates of 96% in 57 GT1b patients with cir-
rhosis [27]. In the OPTMIST II trial evaluating simeprevir plus
sofosbuvir without RBV for 12 weeks in patients with cirrhosis,
26 of 31 (84%) GT1b-infected patients achieved SVR [28].
Treatment with grazoprevir and elbasvir for 12 weeks in
treatment-naïve GT1b-infected patients without cirrhosis
resulted in an SVR12 rate of 93%, and no additional benefit was
gained with co-administration of RBV [29]. In another study of
this combination, all 15 GT1b-infected, PegIFN/RBV prior null
responders with cirrhosis achieved SVR, however the numbers
of patients who received treatment without RBV and for 12 or
18 weeks was not reported [10]. Daclatasvir with sofosbuvir
has only been evaluated with RBV in patients with cirrhosis, in
whom all 11 genotype 1b patients achieved SVR12 [30]. Finally,6 vol. 64 j 301–307
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the triple combination of daclatasvir, asunaprevir, and beclabuvir
led to a 96% response rate in 27 GT1b-infected patients with cir-
rhosis [15]. While difficult to compare across studies, these data
clearly show that OBV/PTV/r and DSV is a highly effective inter-
feron and RBV-free regimen for GT1b-infected patients with
cirrhosis.
The disease characteristics of the patients enrolled in this
study were comparable to the GT1b-infected population receiving
12 weeks of OBV/PTV/r and DSV plus RBV in the phase III
TURQUOISE-II trial (Supplementary Table 1) [9]. Patients with less
well documented experiences of prior treatment were permitted
in this study, making comparisons to prior types of virologic fail-
ure across the two studies difficult. The two study populations
were similar in terms of baseline indices of liver disease severity
including platelet count, albumin, total bilirubin, alpha fetopro-
tein, and FibroTest. Although the FibroScan cut-off for inclusion
in this study was 12.5 kPa compared to 14.6 kPa in the
TURQUOISE-II trial, all but five patients in this study with
FibroScanmeasurements had values above 14.6 kPa, and themed-
ian value was 19 kPa with 20 patients (48%) above 20 kPa.
Nonetheless, efficacy in both studies was exceedingly high, with
the only GT1b failure being a prior partial responder in
TURQUOISE-II with elevated alpha fetoprotein and thrombocy-
topenia at baseline. Similarly, 100% of 301 GT1b-infected patients
without cirrhosis administered OBV/PTV/r and DSV without RBV
achieved SVR12, including 91 with prior treatment experience
and 32 prior null responders [22]. Baseline factors suggestive of
portal hypertension or more advanced liver disease including
thrombocytopenia, hypoalbuminemia, and FibroScan score
>20 kPa, which have been shown to predict lower rates of
response with some DAA regimens [27,28], did not impact SVR
rates, consistent with observations in this population receiving
OBV/PTV/r and DSV plus RBV [31]. These findings suggest that
RBV is not required with OBV/PTV/r and DSV in the treatment of
HCV GT1b patients with cirrhosis, regardless of prior
PegIFN/RBV treatment response or surrogate markers of portal
hypertension.
Although these results show that RBV is not required for GT1b
patients with cirrhosis, all 3 DAAs are likely required for optimal
efficacy with 12 weeks of treatment. In the PEARL-I study,
patients were treated with OBV/PTV/r without DSV for 24 weeks
[32]. SVR rates of 97.9 and 96.2% were reported for treatment-
naïve and treatment-experienced GT1b patients with cirrhosis,
respectively. The results from both TURQUOISE-II and now
TURQUOISE-III demonstrate the additional value of DSV, which
has a better side effect profile than RBV and allows for shorter
treatment duration.
In the absence of RBV, trough plasma concentrations of OBV,
PTV, r, DSV, and DSV M1 metabolite were comparable to this reg-
imen administered with RBV in TURQUOISE-II. However, the 61%
higher PTV Ctrough values observed in TURQUOISE-III compared to
TURQUOISE-II could be due to the smaller number of samples
analyzed coupled with high variability observed with PTV in both
studies (Table 3). The results are consistent with the renal elim-
ination of RBV that would not interfere with the hepatic metabo-
lism of OBV, PTV, r, and DSV [19,33,34].
A limitation of this study includes the open-label, single-arm,
non-comparator design; however, safety comparisons for the
3-DAA regimen with RBV to placebo, or to 3-DAA without RBV,
were performed in phase III studies. Rates of AEs, serious AEs,
and some laboratory abnormalities for OBV/PTV/r and DSV in thisJournal of Hepatology 201study were numerically lower than that of OBV/PTV/r and DSV
plus RBV in the TURQUOISE-II study, presumably due to the lack
of RBV in this study (Supplementary Table 2). No new safety sig-
nals were identified compared to the reported safety profile of
this RBV-free regimen in HCV GT1-infected patients without
cirrhosis [20,21]. The majority of laboratory abnormalities,
particularly events of hyperbilirubinemia, were influenced by
pre-existing liver disease due to the permissive inclusion/
exclusion criteria of this study. One patient experienced AEs
which were considered severe (and serious), attributable to con-
comitant medication and DAAs. This regimen was well tolerated
and no patient prematurely discontinued study drug.
In conclusion, the 12-week 3-DAA regimen of OBV/PTV/r and
DSV achieved an SVR12 rate of 100% in previously PegIFN/RBV
treated and untreated patients with HCV GT1b infection and
compensated cirrhosis. Treatment was well tolerated with a
low rate of serious AEs and no premature treatment discontinu-
ations. Based on a cross-study comparison in a similar patient
population, the rates of common AEs, anemia, and hyperbiliru-
binemia were lower in this study without RBV than was observed
in TURQUOISE-II where RBV was given. These results suggest that
OBV/PTV/r and DSV for 12 weeks is a highly efficacious treatment
for GT1b patients with compensated cirrhosis, and RBV is not
required to maximize SVR rates.Financial support
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